BeiGene, Ltd. (NASDAQ:BGNE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $253.69.

A number of analysts have recently commented on the company. TD Cowen boosted their price target on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. upped their price target on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 22nd. Morgan Stanley reaffirmed an “overweight” rating and set a $300.00 price target on shares of BeiGene in a research note on Tuesday, December 3rd. Finally, StockNews.com started coverage on shares of BeiGene in a report on Sunday. They set a “hold” rating for the company.

BeiGene Stock Performance

The firm has a 50 day moving average price of $194.32 and a 200 day moving average price of $188.98. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The company has a market capitalization of $18.03 billion, a P/E ratio of -22.42 and a beta of 0.57. BeiGene has a 12 month low of $126.97 and a 12 month high of $248.16.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. During the same quarter last year, the company earned $2.01 earnings per share. The firm’s revenue was up 28.2% compared to the same quarter last year. On average, sell-side analysts forecast that BeiGene will post -5.64 earnings per share for the current year.

Insider Buying and Selling at BeiGene

In other news, insider Xiaodong Wang sold 40,468 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $187.27, for a total value of $194,202,173.59. Following the completion of the transaction, the director now owns 791,493 shares in the company, valued at $148,222,894.11. The trade was a 56.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,119,245 shares of company stock valued at $209,700,084 in the last ninety days. 7.43% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BeiGene

Several hedge funds and other institutional investors have recently modified their holdings of BGNE. Baillie Gifford & Co. increased its position in BeiGene by 0.6% during the 3rd quarter. Baillie Gifford & Co. now owns 3,705,756 shares of the company’s stock worth $831,979,000 after purchasing an additional 23,807 shares in the last quarter. FMR LLC lifted its stake in shares of BeiGene by 0.8% in the 3rd quarter. FMR LLC now owns 1,660,011 shares of the company’s stock valued at $372,689,000 after acquiring an additional 12,855 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of BeiGene by 74.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 667,166 shares of the company’s stock valued at $149,785,000 after acquiring an additional 285,784 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in BeiGene by 160.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 225,854 shares of the company’s stock worth $50,706,000 after acquiring an additional 138,978 shares during the last quarter. Finally, Affinity Asset Advisors LLC increased its holdings in BeiGene by 33.9% in the 2nd quarter. Affinity Asset Advisors LLC now owns 110,000 shares of the company’s stock worth $15,694,000 after purchasing an additional 27,857 shares in the last quarter. Institutional investors own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.